Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

Liebowitz, Michael R.; Manley, Amy; Padmanabhan, S. Krishna; Ganguly, Rita; Tummala, Raj; Tourian, Karen A.

doi:10.1185/03007990802161923

Cited by 128 publications

(117 citation statements)

References 24 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Studies investigating desvenlafaxine at lower doses (ie, 50 and 100 mg/d) have demonstrated better tolerability and lower occurrences of AEs [14,15,20].…”

Section: Discussionmentioning

confidence: 99%

“…At the time the study was designed and conducted, 200 mg was believed to be the upper range of therapeutic doses that would be available in clinical practice. However, the results of subsequent clinical trials [14,15] demonstrated that the optimal dose was considerably lower, and 50 mg is now the recommended daily therapeutic dose for MDD in the United States.…”

Section: Introductionmentioning

confidence: 99%

“…Clinical trials of desvenlafaxine administration in healthy adults [13] and in patients with MDD [14,15] have also demonstrated sustainedrelease characteristics that support once-daily administration. For clinical use, it is important to determine if the type of food intake affects pharmacokinetic behavior, as variability could result in unpredictable clinical effects and might necessitate specific dosing guidelines.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Food on the Pharmacokinetics of Desvenlafaxine in Healthy Subjects

Nichols¹,

Richards²,

Behrle³

et al. 2012

JBB

View full text Add to dashboard Cite

“…Studies investigating desvenlafaxine at lower doses (ie, 50 and 100 mg/d) have demonstrated better tolerability and lower occurrences of AEs [14,15,20].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Food on the Pharmacokinetics of Desvenlafaxine in Healthy Subjects

Nichols¹,

Richards²,

Behrle³

et al. 2012

JBB

View full text Add to dashboard Cite

“…Desvenlafaxine succinate which is a major active metabolite of venlafaxine, seems to have lower sexual adverse effects in women compared with men, although these studies have relied on spontaneous self -report only [32,33]. Mirtazapine stimulates noradrenergic and serotonergic activity by its agonist effects on postsynaptic 5 -HT1A receptors and concurrent antagonist effects on 5 -HT2 and 5-HT3 receptors.…”

Section: Role Of Agents With Dual Actions On Serotonin and Norepinephmentioning

confidence: 99%

Sexual Dysfunctions in Depression

J¹,

Rao²,

Chandran³

et al. 2017

Clin Depress

View full text Add to dashboard Cite

Sexual dysfunction is one of the common symptoms seen in depression. Presentations include decreased libido, erectile dysfunction, arousal difficulties and orgasm related dysfunctions. The probable causes of sexual dysfunction in such patients are complex and biological, psychological as well as psychosocial factors are likely to play an important role. Sexual dysfunction could also occur as an adverse effect of anti-depressants although it is difficult to establish whether the dysfunction is due to the illness or the medication. Awareness among professionals about sexual dysfunction is essential as it can have a profound impact in terms of relationship conflict, marital satisfaction, quality of life and compliance with treatment in patients with depression.

show abstract

“…[31][32][33][34][35][36] Several published abstracts were also reviewed: including a fl exible dose trial of DVS 200 to 400 mg, 37 a trial comparing DVS 50 and 100 mg to placebo with a duloxetine reference arm, 8 as well as two unpublished pooled analyses, the fi rst involving 7 short-term trials with DVS doses between 100 and 400 mg 39 and the second from 2 trials with DVS at 50 and 100 mg. 40 Other studies of DVS as a treatment for vasomotor symptoms of menopause and pain were not reviewed. No published trials for generalized anxiety disorder or other anxiety disorders were located.…”

Section: Effi Cacy In Clinical Trialsmentioning

confidence: 99%

Desvenlafaxine in the treatment of major depressive disorder

Lourenço

Kennedy²

2009

NDT

View full text Add to dashboard Cite

Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) antidepressants has improved the treatment of MDD. Desvenlafaxine succinate (DVS) is the succinate salt of the isolated major active metabolite of venlafaxine, O-desmethylvenlafaxine: it is the third SNRI to become available in the United States, and was approved in 2008 by the US Food and Drug Administration (FDA) for the treatment of MDD. Early investigations showed therapeutic effi cacy for doses between 50 and 400 mg/day; however in doses above 100 mg/day there were incremental increases in side effects. Nausea was the most frequent adverse effect. Hence the recommended dosing for DVS is in the 50 to 100 mg range. Desvenlafaxine is excreted in urine, it is minimally metabolized via the CYP450 pathway, and is a weak inhibitor of CYP2D6. A reduced risk for pharmacokinetic drug interactions is a potential advantage over other SNRI. Further head-to-head trials involving comparisons of DVS in the 50 to 100 mg dose range with currently available SSRI and SNRI antidepressants are required. Evidence for relapse prevention is available in the 200 to 400 mg dose range, but this needs to be demonstrated in the 50 to 100 mg dose range, as well as health economic measures and quality of life evaluations.

show abstract

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

Cited by 128 publications

References 24 publications

Effect of Food on the Pharmacokinetics of Desvenlafaxine in Healthy Subjects

Effect of Food on the Pharmacokinetics of Desvenlafaxine in Healthy Subjects

Sexual Dysfunctions in Depression

Desvenlafaxine in the treatment of major depressive disorder

Contact Info

Product

Resources

About